ArticleNPJ precision oncology2025
Case report: a R0 resection successfully induced by T-DXd plus PD-1 inhibitor regimen in a primary unresectable stage IIIB NSCLC with ERBB2-mutation.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Case Report: Neoadjuvant chemoimmunotherapy achieving pathological complete response in two cases of stage III EGFR-mutant NSCLC with high PD-L1 expression.Frontiers in oncology · 2026Article
- Redefining Therapeutic Boundaries: PD-1 Blockade Facilitates Surgical Cure in EGFR-TKI Refractory EGFR-Mutant NSCLC with Pleural Metastases.OncoTargets and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemoradiotherapy (CRT) with consolidative immunotherapy(IO) remains the standard care for unresectable stage III NSCLC, yet survival remains suboptimal in molecular subgroups. Emerging targeted therapies offer the potential for converting unresectable cases to resectable status. We present a 54-year-old female with stage IIIB (T1cN3M0) ERBB2 exon 20-mutated lung adenocarcinoma (PD-L1 50%) and supraclavicular metastasis. After three cycles of ERBB2-targeted antibody-drug conjugate combined with programmed death-1 (PD-1) inhibitor, transient Grade 1 interstitial lung disease resolved with steroids. Serial imaging revealed 58% tumor regression, enabling successful R0 resection via VATS lobectomy with lymphadenectomy. Histopathological analysis confirmed complete pathological response in primary and nodal lesions, corroborated by undetectable postoperative minimal residual disease. The patient remained recurrence-free at a 9-month follow-up. This induction targeted-IO strategy enabled surgical conversion in ERBB2-mutant NSCLC with durable remission and acceptable toxicity, warranting investigation in molecular subgroups with limited CRT-IO benefit.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.